<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713984</url>
  </required_header>
  <id_info>
    <org_study_id>TMMU-BTC-005</org_study_id>
    <nct_id>NCT02713984</nct_id>
  </id_info>
  <brief_title>A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer</brief_title>
  <official_title>A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhi Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southwest Hospital, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chimeric antigen receptor T cells (CAR-T) therapy has not yet been fully explored in solid
      tumors. Human epidermal growth factor receptor-2(HER2) is widely expressed in cancers.
      Investigators have developed anti-HER2 CAR-modified T cells and validated the efficiency
      targeting HER2-positive cancer in preclinical studies. This study is aimed to confirm its
      adverse effects including cytokine storm response and any other adverse effects. In addition,
      CAR-T cells persistence, tumor elimination and disease status after treatment will be
      evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the toxicity profile of the HER2 targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.</measure>
    <time_frame>3 years</time_frame>
    <description>Observe and handle the toxicity profile of the HER2 targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival time of Anti-HER2 CAR T cells in vivo.</measure>
    <time_frame>1 year</time_frame>
    <description>Detect the existence of CAR-T cells in the blood of participants through qPCR or flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of anti-HER2 CAR T cells to confirm the ability of CAR T cells to eliminate HER2 positive cancer cells</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate the anti-tumor efficacy of CAR-T therapy by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 and Immune-Related Response Criteria（iRECIST）.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose (MTD) of HER2 targeted CAR T cells</measure>
    <time_frame>4 weeks</time_frame>
    <description>Determine the maximum tolerated dose of each participant through the grades of side effects.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Glioma</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>HER2 positive cancers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed and refractory cancer of HER2 expression will be treated with anti-HER2 CAR-T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-HER2 CAR-T</intervention_name>
    <description>HER-2-targeting CAR-T cells infusion in HER2 positive cancers</description>
    <arm_group_label>HER2 positive cancers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Relapsed or refractory HER2 positive cancer.

          2. KPS&gt;60.

          3. Life expectancy&gt;3 months.

          4. Gender unlimited, age from 18 years to 80 years.

          5. Assessable lesions with a minimum size of 10mm by CT scan or MRI.

          6. Acceptable organ function

             Hematology:

               -  Absolute neutrophil count greater than 800/mm^3 without the support of
                  filgrastim.

               -  White blood cell (WBC) (&gt; 2000/mm^3).

               -  Platelet count greater than 50,000/mm^3.

               -  Hemoglobin greater than 9.0 g/dl.

             Chemistry:

               -  Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less or
                  equal to 3 times the upper limit of normal (patients without liver metastasis) or
                  6 times the upper limit of normal (patients with liver metastasis).

               -  Serum creatinine less or equal to 3 times the upper limit of normal

               -  Total bilirubin less than or equal to 3 times the upper limit of normal.

          7. No other serious diseases(autoimmune disease, immunodeficiency etc.).

          8. Adequate cardiac function(LVEF≥40%).

          9. No other tumors.

         10. Patients volunteer to participate in the research.

        Exclusion Criteria:

          1. Allergic to cytokines.

          2. Uncontrolled active infection.

          3. Acute or chronic GVHD.

          4. MODS.

          5. Treated with T cell inhibitor.

          6. HIV affected.

          7. Other situations improper for the research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng Qian, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheng Qian, MD,PhD</last_name>
    <phone>0086-023-68765461</phone>
    <email>cqian3184@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chengcheng Zhang, MD</last_name>
    <phone>0086-13883587876</phone>
    <email>zccszcg@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southwest Hospital of Third Millitary Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng Qian, MD,PhD</last_name>
      <phone>0086-023-68765461</phone>
      <email>cqian3184@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Chengcheng Zhang, MD</last_name>
      <phone>0086-13883587876</phone>
      <email>zccszcg@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cheng Qian, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhi Yang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chengcheng Zhang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Hospital, China</investigator_affiliation>
    <investigator_full_name>Zhi Yang</investigator_full_name>
    <investigator_title>Researcher of Biotherpy Center</investigator_title>
  </responsible_party>
  <keyword>HER2 CAR-T</keyword>
  <keyword>safety</keyword>
  <keyword>efficiency</keyword>
  <keyword>refractory and relapsed cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

